Poststroke cognitive impairment and dementia (PSCID) is a major source of morbidity and
mortality after stroke worldwide. PSCID occurs as a consequence of ischemic stroke …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because
clinical symptoms are strongly correlated with tau aggregates, drug development and …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both
amyloid and tau pathology in clinical settings, but their performance in heterogeneous …

Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …

Neuronal cell loss is a defining feature of Alzheimer's disease (AD), but the underlying
mechanisms remain unclear. We xenografted human or mouse neurons into the brain of a …